Kura Oncology to Host Virtual Investor Event on December 9, 2024
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH
直播網絡研討會和電話會議將討論在ASH上更新的KOMEt-007聯合試驗的數據展示
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. ET / 5:00 a.m. PT on Monday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company's oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego.
聖地亞哥，2024年12月2日（全球新聞通訊）—— kura oncology, Inc.（納斯達克：KURA），一家致力於實現癌症治療精準醫療承諾的臨床階段生物製藥公司，今日宣佈將於2024年12月9日星期一上午8:00（東部時間）/ 上午5:00（太平洋時間）舉辦虛擬投資者活動，討論公司的口服選擇性美尼抑制劑ziftomenib的KOMEt-007聯合試驗，更新的臨床數據將在第66屆美國血液學會（ASH）年會上展示，地點在聖地亞哥。
The virtual event will feature members of the management team along with investigators from the KOMET-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be available here and in the Investors section of Kura's website, with an archived replay available shortly after the event.
虛擬活動將有管理團隊成員及KOMEt-007試驗的研究人員參與。國內撥打（800）715-9871和國際撥打（646）307-1963可訪問現場直播，並輸入會議ID：4326549。直播網絡研討會將在此處和Kura網站的投資者專區提供，活動結束後將很快提供錄像回放。
About Kura Oncology
關於kura oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.
Kura oncology是一家致力於實現癌症治療精準醫療承諾的臨床階段生物製藥公司。公司的管線包括針對癌症信號通路的小分子藥物候選者。Ziftomenib是一種每日一次的口服美尼抑制劑，是首個也是唯一獲得美國食品和藥物管理局（FDA）突破性療法認定的用於治療復發/難治（R/R）NPM1突變急性髓性白血病（AML）的研究治療。2024年11月，Kura與協和藥品工業有限公司簽署了一項全球戰略合作協議，以開發和商業化ziftomenib用於AML和其他血液惡性腫瘤。在R/R NPM1突變AML的II期註冊導向試驗中的入組已經完成，雙方預計將在2025年提交新藥申請。Kura還在進行一系列臨床試驗，以評估ziftomenib與新診斷和R/R NPM1突變及KMT2A重排的AML的當前標準療法聯合使用的效果。KO-2806，一種下一代法尼醇轉移酶抑制劑，正在作爲單藥和與靶向治療組合的I期劑量遞增試驗中進行評估。Tipifarnib，一種有效且選擇性的FTI，目前正在與alpelisib聯用的I/II期試驗中，適用於PIK3CA依賴的頭頸部鱗狀細胞癌。如需更多信息，請訪問Kura的網站並在X和LinkedIn上關注我們。
Kura Contacts
kura oncology 聯繫人
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
投資者:
Pete De Spain
執行副總裁，投資者關係
企業通訊
858-500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
媒體:
Cassidy McClain
副總裁
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
譯文內容由第三人軟體翻譯。
